Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2010

View Archived Issues

Amplyx Pharmaceuticals claims new HIV protease inhibitors

RARB, SLITS and WIF1 gene methylation status may predict cervical cancer

SPIRAL data show noninferiority of ritonavir- vs. raltegravir-based therapy in HIV-1 infection

Gardasil HPV vaccine is safe and efficacious in HM and MSM

PET imaging agent AV-133 distinguishes Alzheimer's disease from DLB

Inflammatory cytokines identified as putative biomarkers for AD

MabVax begins phase II trial of trivalent ganglioside vaccine in sarcoma

EMA recommends restricting modafinil use

VM Discovery discloses new Trk-A inhibitors

New GlyT-1 inhibitors discovered at Vanderbilt University

New sialidase inhibitors described at Simon Fraser University

NovaBay's NVC-422 is safe and efficacious against impetigo in phase II trial

Sumitomo Chemical presents new mPGES-1 inhibitors

Akebia begins phase IIa trial of AKB-6548 for anemia in patients with CKD

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

Almirall and Pfizer join to commercialize Conbriza for osteoporosis in Spain

MedImmune begins shipping FluMist influenza vaccine in U.S.

NovImmune and Genentech collaborate on IL-17-directed antibody

CHMP issues positive opinion on Twynsta for hypertension

Abraxane approved in Japan for breast cancer

FDA approves Oxford BioMedica's phase II trial of MVA-5T4 in prostate cancer

FDA approves Aricept 23-mg tablet for Alzheimer's disease

Enrollment begins in phase III trial of BHR-100 for traumatic brain injury

Sanofi-aventis expresses reservations regarding FDA approval of new version of enoxaparin sodium

Cerenis Therapeutics raises funds to develop HDL therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...